The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes:
Cross-border dialogue: An international survey of regulators on phage therapy.
Alvarez RD, Årdal C, Classen AY, Nagel TE, Ceyssens PJ, German GJ. Int J Antimicrob Agents. 2025 Dec;66(6):107614
Phage therapy.
Mikael Skurnik, Sivan Alkalay-Oren, Maarten Boon, Martha Clokie, Thomas Sicheritz-Pontén,Krystyna Dąbrowska, Graham F. Hatfull, Ronen Hazan, Matti Jalasvuori, Saija Kiljunen, Rob Lavigne, Danish J. Malik, Ran Nir-Paz & Jean-Paul Pirnay. Nature Reviews Methods Primers 2025. 5, Article number: 10
2025 ICM: Role of Unconventional Medications.
Suh GA; ESGNTA; Scobie A; ESGNTA; Piuzzi NS, Bartak V, Anyaehie UE, Arciola CR, Batailler C, Benes M, Binlaksar R, Buttaro M, Damioli LE, de Beaubien BC, Dietz MJ, Doub JB, Elmenawi KA, Falez F, Ferry T; ESGNTA; Goswami K, Kucukdurmaz F, Li B, Metsemakers WJ, Moriarty TF, Saeed M, Shah RP, Springer B, Tootsi K, Tsiridis E, Urish KL. J Arthroplasty. 2025 Oct 31:S0883-5403(25)01395-6
Phages and phage-borne enzymes as new antibacterial agents.
McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.
Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023
Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.
If you have questions or comments for our study group, we warmly invite you to contact us!
Registration for ESCMID Global 2026 in Munich is now open.
Register now to get the early registration fee and attend the world’s most eminent event in the field of infection.